Previous findings demonstrate that upon the knockout of GOT2 using CRISPR/Cas9 technology, pancreatic cancer cells deficient in GOT2 exhibited markedly restricted growth in immunocompetent syngeneic mouse models. The gene discussed is GOT2; the disease is pancreatic neoplasm.